Replies to post #127266 on Biotech Values

[DewDiligence]

The lack of FOB program disclosure is industry-wide and the danger lies in too many companies pursuing the same biologic. Which companies are making progress in FOB and which are hitting dead ends? We don't even know what they are working on so it's hard to tell.

It’s a pretty good bet that one of MNTA’s FoB programs is Orencia (#msg-56429332, #msg-52853238, #msg-56471065). Another good bet is that MNTA is working on one or more of the TNF-alpha drugs (#msg-59857407).